

**MPN Horizons 2021**  
**12-14 November 2021**  
**Starting at 12:45 Central European Time (CET)**  
**Draft AGENDA**

<b>DAY 1: Friday 12<sup>th</sup> November 2021</b>	
<p><b>12:00 - 12:45</b> 45 min</p>	<p><b>“MPN 101- What are MPNs?”</b> - <i>Prof. Martin Ellis, pre-recorded session available on request to first-time participants.</i></p>
<p><b>12:45-13:15</b> 30 min</p>	<p><b>Opening</b></p> <ul style="list-style-type: none"> <li>• Welcome by Werner Zinkand, Chair of MPN AN and Giora Sharf</li> <li>• MPN AN Update - <a href="#">Jon Mathias</a> and <a href="#">Felice Bombaci</a></li> </ul>
<p><b>13:15 - 13:30</b> 15 min</p>	<p><b>Break</b></p>
<p><b>13:30 - 15:00</b> 90 min</p>	<p><b>Medical session #1: The future of MPNs</b></p> <p><b>Chairs:</b> <a href="#">Jon Mathias</a> and <a href="#">Mirjana Babamova</a></p> <p><i>This session will provide an update to current clinical trials and pre-trial information, future of MPN new drugs and new diagnostic tools.</i></p> <ul style="list-style-type: none"> <li>• <b>Besremi: The New Interferon</b> (15 min) Speaker: <a href="#">Prof. Dr Heinz Gisslinger, Wien, Austria</a></li> <li>• <b>Future of MPN New Drugs</b> (25 min) Speaker: <a href="#">Prof. Dr Ruben Mesa, Mays Cancer Center, USA</a></li> <li>• <b>Update to current clinical trials</b> (25 min) Speaker: <a href="#">Dr Claire Harrison, Guy's and St. Thomas' Hospital, London UK</a></li> </ul> <p align="center"><b>Q &amp; A 25 min</b></p>
<p><b>15:00 - 15:30</b> 30 min</p>	<p><b>Break</b></p>

<p><b>15:30 - 17:00</b></p> <p>90 min</p>	<p><b>Medical and Advocacy Session #1: Covid and MPN - What have we learned?</b></p> <p><i>This combined medical and advocacy session will continue conversations on covid 19 and present main findings between viruses like covid and MPNs and in connection with vaccines, especially MRNs types. Session will also address how covid influenced activities of patient groups (fundraising) and present best practices.</i></p> <p><b>Chairs: Param Puthem and Lyat Granati Spinoza</b></p> <ul style="list-style-type: none"> <li>● The Main Finding Of Connection Between Covid 19 and MPNs, including Vaccines <i>(20 min)</i>  <b>Speaker: Prof Tiziano Barbui, Bergamo, Italy</b></li> <li>● How Patient Groups Engage With Their Communities in Covid Times – Best practices       <ul style="list-style-type: none"> <li>➤ Fundraising in Covid Times –<b>Eunice, AMAL, Uganda (10min)</b></li> <li>➤ Role of Data and Technology in Patient Engagement- Digital tools for the New Reality - <b>Jonathan Mathias, MPN Voice, UK (10 min)</b></li> <li>➤ How To Use New media to Increase Your Engagement With The Patient Community During Covid? - <b>Andrew Schorr, Patient Power (10min)</b></li> <li>➤ <b>Best practice from MPN community</b>  <i>“How did your organisation adapt to Covid and what did you learn for the future when the pandemic is over.” (10min)</i></li> </ul> </li> </ul> <p style="text-align: center;"><b>Q &amp; A 30 min</b></p>
<p><b>17:00</b></p>	<p><b>End of day 1</b></p>

<b>DAY 2: Saturday 13<sup>th</sup> November 2021</b>	
<b>13:00 - 13:30</b> 30 min	<b>Regional meetings summary - Feedback</b>
<b>13:30 - 15:00</b> 90 min	<p><b>Medical session #2: Today and Tomorrow in MPN Therapy</b></p> <p><i>This session will address different ways to prevent progression. How do you do the test and understand that you are progressing or are in a high-risk group? What options are there to prevent its progression, either by a new trial or by a new drug? It will also explore the possibility of transplant from a physician and patient perspective.</i></p> <p><b>Chairs: Kapila Vigés and Werner Zinkand</b></p> <ul style="list-style-type: none"> <li>• Status of Genetic Testing and Other Biomarkers (20 min)  <b>Speaker: Prof Gregor Hoermann, Munich Leukemia Laboratory, Germany (20 min)</b></li> <li>• Key Criteria for Disease Progression Beyond Fibrotic and Leukemic Transformation in Each of the MPNs? How can we prevent? (20 min)  <b>Speaker: Dr. Andrew Kuykendall, Molfit Caven Center, Tampa</b></li> <li>• The role of Transplant in MPNs- Doctors and patients' Perspective (30 min)  <b>Speakers: Prof Nicolaus Kroeger, University Hospital Hamburg (20min) and Joachim Urmelt (10min)</b></li> </ul> <p style="text-align: center;"><b>Q &amp; A session 20 min</b></p>
<b>15:00 - 15:30</b> 30 min	<b>Break</b>
<b>15:30 - 17:00</b> 90 min	<p><b>Advocacy Session #2: Living well with MPN</b></p> <p><i>This session will explore how to be well and live well with MPN. What do patients need to know?</i></p> <p><b>Chairs: Lyat Granati Spinoza and Giora Sharf</b></p> <ul style="list-style-type: none"> <li>• Nutrition (20 min)  <b>Speakers: Prof Angela Fleischmann, UCLA and Natalie Cook, dietician with PV</b></li> <li>• Evidence Based Approach to Use Complementary Strategies (20 min)  <b>Speaker: Prof. Krisztina Gowin, University of Arizona</b></li> <li>• Living with MPN Fatigue (20 min)  <b>Speaker: Dr Elizabeth Pearson, Peter MacCallum Cancer Centre, Australia</b></li> </ul> <p style="text-align: center;"><b>Q &amp; A session 30 min</b></p>

<b>DAY 3: Sunday 14<sup>th</sup> November 2021</b>	
<b>13:00 - 14:30</b>  <i>90 min</i>	<b>Medical session #3: Special cases in MPNs</b>  <b>Chairs: Kapila Vigés and Mirjana Babamova</b> <ul style="list-style-type: none"> <li>• MPN in Young Patients - Under 40 years old  <i>Speaker: Prof. Eva Lengfelder, Mannheim Heidelberg, Germany (20min)</i></li> <li>• Pregnancy in MPN  <i>Speaker: Prof. Martin Griesshammer, Germany (20min)</i></li> <li>• Comorbidities in MPNs  <i>Speaker: Prof. Claire Harrison, Guy's and St. Thomas' Hospital, London UK (20min)</i></li> </ul> <p style="text-align: center;"><b>Q &amp; A session 30 min</b></p>
<b>14:30 - 15:00</b>  <i>30 min</i>	<b>Break</b>
<b>15.00 - 16:30</b>  <i>90 min</i>	<b>Advocacy Session #3: MPN Next Steps and Future</b>  <b>Chairs: Felice Bombaci and Jon Mathias</b> <ul style="list-style-type: none"> <li>• “The Voice of Younger MPN patients”  <i>Speakers: Alice Watson, Lennart Rusch and Caroline Thomas (30 min)</i></li> <li>• History, Work and Future of MPN RF  <i>Speaker : Kapila Vignes, MPN RF, USA (15 min)</i></li> <li>• Involvement of Patient Advocate Groups in HTA <i>(15min)</i>  <i>Speaker: Werner Zinkand, Germany</i></li> </ul> <p style="text-align: center;"><b>Q &amp; A session 30min</b></p>
<b>16:30 - 17:00</b>  <i>30 min</i>	<b>Concluding remarks by Werner Zinkand and Mirjana Babamova</b>